Rhythm Metabolic Inc

Rhythm Pharmaceuticals is a Boston-based company dedicated to transforming the lives of patients and their families affected by hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. They are focused on developing precision medicines that address the root cause of these conditions by targeting the MC4R pathway, which regulates weight and hunger. Through their translational research and clinical development programs, Rhythm Pharmaceuticals aims to provide innovative therapies for rare genetic diseases of obesity.

With a strong emphasis on patient care, Rhythm Pharmaceuticals is committed to advancing the understanding and treatment of hyperphagia and severe obesity. They leverage the largest known DNA database focused on obesity to drive their research efforts and develop therapies for rare obesities linked to variants in specific genes with relevance to the MC4R pathway. By pioneering new approaches and therapies, Rhythm Pharmaceuticals is at the forefront of transforming the care of individuals living with rare genetic diseases of obesity.

Generated from the website